Phase I/II – First Administration

443 trials 187 recruiting

Filter these 443 trials by condition, country, sponsor and more.

Open in Search →

Phase 1/2 study testing for the first time in humans a novel drug, STAR0602, to selectively stimulate T cells for the treatment of subjects … Recruiting

2023-505334-10-01 Unresectable, Locally Advanced, or Metastatic Solid Tum 2024-10-30
Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF… Recruiting

2024-511858-44-00 Inclusion Body Myositis 2024-10-24
Repairing Peri-Anal Fistulas with regenerative cell therapeutics (REP-PAF) Recruiting

2022-502659-73-01 Crypto-glandular perianal fistula 2024-10-09
BORTEM 17 Recruiting

2024-515142-16-00 Grade IV recurrent glioma which includes both glioblast 2024-10-03
A clinical trial to learn about the safety and effects of STX-241, a new oral anticancer drug for the treatment of patients with advanced lu… Recruiting

2023-510203-21-00 locally advanced or metastatic non-small cell lung canc 2024-09-24
A study of niraparib in combination with abemaciclib for late line treatment of ovarian cancer: a single center, open label, single arm, pha… Recruiting

2022-501910-79-01 Ovarian cancer 2024-09-18
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with An… Recruiting

2024-512589-32-00 Angelman syndrome 2024-09-16
A Phase I/II Study of AZD5863 in Adult Participants with Advanced or Metastatic Solid Tumors Recruiting

2023-504139-42-00 Advanced or metastatic solid tumors 2024-09-06
A first-in-human study to investigate the safety and tolerability of a new antibody-guided drug delivery treatment for patients with therapy… Recruiting

2024-511074-80-01 Platinum-resistant high-grade ovarian cancer (PROC) or 2024-09-06
A Phase 1/2, Multicenter Study Evaluating the Safety, Tolerability, and Biodistribution of RCT2100 with Single-Ascending Doses in Healthy Pa… Recruiting

2024-512169-15-00 Cystic Fibrosis 2024-08-28
Long-term safety bucket trial with NVDX3, an osteogenic implant of human allogenic origin Recruiting

2024-511661-11-01 Distal Radius fracture 2024-08-22
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas Recruiting

2023-503550-13-00 Large Granular Lymphocytic Leukemia or Cytotoxic Lympho 2024-08-08
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML. Recruiting

2023-505806-41-00 Acute myeloid leukemia 2024-08-01
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with ad… Recruiting

2023-504199-19-00 Solid Tumours 2024-06-26
Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting

2023-508139-29-00 Advanced or metastatic solid tumors 2024-06-26
A trial to learn if AZD0305 alone and in combination with other cancer treatments is safe and works in adults with multiple myeloma Recruiting

2023-508590-89-00 Multiple Myeloma 2024-06-25
Treatment of difficult-to-heal wounds with stem cells included in a gel consistency dressing Recruiting

2023-505017-25-02 Hard-to-heal-wounds 2024-06-10
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE) Recruiting

2023-504251-27-00 Locally Advanced or Metastatic Solid Tumors Harboring a 2024-05-27
Safety, Tolerability, PK, PD, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia Recruiting

2023-505995-31-00 Glanzmann Thrombasthenia 2024-05-03
A Phase I/IIa multicenter study evaluating the safety and efficacy of CAR20(NAP)-T in patients with relapsed/refractory B cell lymphoma (CAR… Recruiting

2024-511844-18-00 Relapsed or refractory CD20+ diffuse large B-cell lymph 2024-05-02
A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in particip… Recruiting

2023-507305-33-00 Patients with ER+ HER2- advanced breast cancer and pati 2024-04-29
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory… Recruiting

2023-508355-39-00 Relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leu 2024-04-20
Phase I-IIa, randomized, controlled, open-label, single-center clinical trial to evaluate the safety, feasibility, and evidence of efficacy … Recruiting

2023-506913-23-00 Cleft lip and palate 2024-04-17
A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations Recruiting

2023-506759-51-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 2024-03-29